membrane and subsequent acquisition of biological activity Mevastatin is an inhibitor of 3-hydroxy-3-methylglutaryl- (9) . Aberrant Ras function has been considered as an important coenzyme A (HMG-CoA) reductase, the rate-limiting contribution to human colon carcinogenesis, therefore significenzyme in cholesterol synthesis. Butyrate, a short-chain ant progress has been made to antagonize Ras prenylation (7). fatty acid, reduces proliferation and induces differentiation By inhibiting protein isoprenylation, HRIs exert important of human colon cancer cells. The aim of our study was to cellular effects, including a reduction of cell proliferation and determine the effect of mevastatin, alone or in combination an induction of apoptosis (1). Thus, HRIs, such as mevastatin, with butyrate, on proliferation, the cell cycle and apoptosis pravastatin or simvastatin, may have significant antitumour in the human colorectal carcinoma cell line Caco-2. In this activity. This was further supported by two clinical studies report we show that mevastatin combined with butyrate showing a 43% (10) and 19% (11) reduction in the number of synergistically suppressed growth of Caco-2 cells in a dosenewly diagnosed cases of colorectal cancer during a 5-year and time-dependent manner. In addition, incubation with follow-up period in patients with coronary artery disease mevastatin arrested cells in the G 1 phase of the cell cycle receiving pravastatin and simvastatin, respectively. Furtherafter 24 h with a switch to the G 2 /M phase after 72 h. This more, the chemopreventive effect of pravastatin could be was accompanied by a down-regulation of cyclin-dependent augmented by concomitant ingestion of non-steroidal antikinases (cdk) 4 and cdk 6 as well as cyclin D1, while cdk inflammatory drugs (NSAIDs) like aspirin (10). In rodents, 2 and cyclin E protein levels remained unchanged during pravastatin and simvastatin have been shown to reduce mevastatin treatment. Cell cycle inhibitors p21 and p27 were significantly upregulated by mevastatin. The procarcinogen-induced colon cancers by 50-65% (12,13). apoptotic properties of mevastatin were further enhanced Butyrate, a short-chain fatty acid produced by colonic by co-incubation with butyrate. Lastly, the effects of fermentation of dietary fibre, has been shown to modulate mevastatin could be reversed by addition of mevalonate, proliferation and differentiation of normal and neoplastic but not farnesyl-or geranylgeranylpyrophosphate, intercolonocytes (14,15). Butyrate is functionally disparate but mediate products of cholesterol synthesis, to the medium. structurally similar and metabolically related to mevalonate.
Materials and methods

Cell culture
The human colorectal cancer cell lines Caco-2 and HCT-116 were obtained from the American Type Culture Collection (ATCC; Rockville, MD). Caco-2 cells of passages [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] were grown in Dulbecco's modified Eagle medium (DMEM), HCT-116 cells (passages 21-23) were grown in McCoy's 5A medium, both supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin and 100 µg/ml streptomycin under 5% CO 2 and 95% air. Cells were passaged using Dulbecco's PBS containing 0.25% trypsin and 1% EDTA. For treatment with sodium butyrate, mevastatin or mevalonate, cells were cultured in DMEM until nearly confluent. Medium was then removed and replaced by a medium containing either the solvent or 1-2 mM butyrate, mevastatin or mevalonate. Butyrate (Merck-Schuchardt, Hohenbrunn, Germany) and mevalonate (DL-mevalonic acid lactone; Sigma, St Louis, MO) were solubilized in PBS and added to the medium. Mevastatin (Sigma) was solubilized in DMSO. For defining a role of intermediate metabolites of the mevalonate pathway, cells were incubated with 100 µM farnesylpyrophosphate (FPP) or 10 µM geranylgeranylpyrophosphate (GGPP) (Sigma). The medium was changed every other day. Cells were then harvested at the times stated in the figure legends. Fig. 1 . Dose-response curve of Caco-2 cells incubated with increasing Cell counts concentrations of mevastatin for 5 days. Means Ϯ SD, n ϭ 8. Cells were suspended and cultured on 96-well dishes at a density of 2ϫ10 5 /cm 2 until subconfluent. Media was then changed every other day and at given time points cell number was assessed by crystal violet staining.
Results
Medium was removed from the plates and cells were fixed in 5% formaldehyde
Mevastatin enhances the growth inhibitory effect of butyrate for 5 min. After washing with PBS cells were stained with 0.5% crystal violet for 10 min, washed again with PBS and unstained with 33% acetoic acid.
First of all, the effective dose of mevastatin in Caco-2 cells Absorption, which correlates with the cell number, was measured at 620 nm.
was determined. For this purpose, cells were treated with Cytotoxicity was excluded using a LDH kit (Merck, Darmstadt, Germany) various concentrations of mevastatin and cell number was measuring lactate dehydrogenase activity in the supernatant of damaged cells.
assessed after 5 days of incubation. As shown in Figure 1 ,
Cell cycle analysis
mevastatin caused a dose-dependent decrease in cell number.
Cells were seeded in 6-well plates at a density of 15ϫ10 4 /well and allowed
In the first set of experiments, Caco-2 cells were grown to attach for 24 h. Twenty-four hours following treatment cells were washed under standard conditions or incubated with butyratewith PBS and harvested by trypsinization (2.5% trypsin/EDTA solution; containing medium (1 or 2 mM) and treated with mevalonate Gibco, Eggenstein, Germany). DNA contents of cells were measured using a DNA staining kit (CycleTEST PLUS DNA Reagent kit; Becton Dickinson, (2.5 mM), mevastatin (64 µM) or a combination of both.
Heidelberg, Germany). Propidium iodide stained nuclear fractions were
The dosage of mevalonate and mevastatin, respectively, was to calculate the differences between treatment groups in the experiments. Differences were considered significant at P ഛ 0.05.
was most prominent with 64 µM mevastatin (up to 21% caused a dose-dependent decrease in cdk 4 (up to 18%
Means Ϯ SD, n ϭ 8, *P Ͻ 0.05, **P Ͻ 0.01.
with 128 µM mevastatin versus control), cdk 6 (up to 23% with 128 µM mevastatin versus control) and cyclin D1 (up to 45% with 128 µM mevastatin versus control) protein expression, accompanied by an up-regulation of the cell cycle inhibitors p21 (up to 223% with 64 µM mevastatin versus control) and p27 (up to 344% with 64 µM mevastatin versus control), supporting the observed G 1 cell cycle arrest ( Figure  5A and B). However, at higher concentrations (128 µM mevastatin) cell cycle inhibitors p21 and p27 decreased slightly (p21 up to 118% versus control; p27 up to 320% versus control). The decrease in cdk 4 and cdk 6 protein expression as well as the increase of the cdk inhibitors p21 and p27 by mevastatin could be prevented by co-incubation with mevalonate (2.5 mM) ( Figure 5A ). Cdk 2 protein expression decreased significantly with butyrate treatment, as shown in earlier studies (27) , but was not influenced by incubation with mevastatin ( Figure 5C ). The same effect could be observed in terms of cyclin E. The expression of the cell cycle inhibitor p21 increased in both groups by mevastatin treatment, with the more prominent increase in the butyrate group.
In order to assess the specificity of these effects, HCT-116 cells were treated with increasing concentrations of mevastatin. of p27 protein expression (up to 168% with 20 µM mevastatin versus control) ( Figure 6A and B) . versus control). Addition of mevalonate (2.5 mM) reversed
Mevastatin induces apoptosis in Caco-2 cells the effects of mevastatin on the cell cycle (data not shown).
Caco-2 cells were seeded into 96 wells and incubated with Mevastatin down-regulates cdk 4, cdk 6 and cyclin D1 and increasing concentrations of mevastatin (16-256 µM). As upregulates p21 and p27
shown in Figure 7A , mevastatin induced apoptosis in a dosedependent manner, which was not due to cytotoxicity as In order to examine the effect of mevastatin on cell cycle associated proteins, we determined protein expression of cdk measured by lactate dehydrogenase activity in the supernatant. Co-incubation with butyrate (1 mM) further increased apoptosis 2, cdk 4, cdk 6, cyclin D1, cyclin E, p21 and p27 in Caco-2 cells after 3 days of treatment with various concentrations of about 2-4-fold ( Figure 7B ). inhibition of the mevalonate pathway by use of mevastatin, the prototype HMG-CoA reductase inhibitor, enhances the antiproliferative effect of butyrate on the colorectal cancer cell line Caco-2 in a time-and dose-dependent manner. This effect could be reversed by co-incubation with mevalonate, by- concentrations. This is most likely to be due to the higher proliferation rate of HCT-116 cells as compared with CacoDiscussion 2 cells. It is generally accepted that butyrate causes a G 1 arrest in The short-chain fatty acid mevalonate, a precursor in the synthesis of cholesterol and isoprenoids, or its metabolites are several cell lines (29-31). The same effect could be observed with HMG-CoA reductase inhibitors in myeloid leukemia cells, essential for cell growth, whereas its metabolic counterpart, butyrate, inhibits growth of colorectal cancer cells (5, 18, 26, 28) .
human breast cancer cells and mouse fibroblasts (21,23,25). Therefore, we examined the putative influence of the HRI Earlier studies suggested that butyrate's effects may be linked to the inhibition of mevalonate-mediated cell growth (16) . Our mevastatin on the cell cycle and cell cycle relevant proteins in the colorectal adenocarcinoma cell line Caco-2. Flow results are consistent with this hypothesis, demonstrating that cytometry analysis showed that mevastatin led to an early the late switch to the G 2 /M phase, are also involved. The influence of mevastatin on cell cycle related proteins does not arrest of cells in the G 0 /G 1 phase (after 24 h of treatment) and a late arrest in the G 2 /M phase (after 72 h). Again, these seem to be specific of Caco-2 cells, since similar effects could be observed in another colon cancer cell line, HCT-116. effects could be reversed by the addition of mevalonate to the medium.
The induction of apoptosis is another common feature of butyrate and HRI (2, 31, (42) (43) (44) (45) (46) (47) . In the case of butyrate, this Cell cycle is governed by a family of cyclin-dependent kinases (cdks), whose activity is regulated by binding of the seems to be mediated by different mechanisms including elevated levels of the pro-apoptotic protein bak and reduced cyclins, by phosphorylation and by negative regulators, cdk inhibitors, like p21 and p27 (25,32). Cdk 4 and cdk 6 are levels of the anti-apoptotic bcl-2 (45, 48) . In the present study we found that mevastatin also has the ability to induce thought to play a major role in cell cycle progression in early G 1 phase, triggering the phosphorylation of cyclin D, which apoptosis in Caco-2 cells in a dose-dependent manner, which was further enhanced by co-incubation with butyrate. The is responsible for the progression of cells through the G 1 phase of the cell cycle. Cdk 2 activity is first evident during the underlying mechanisms may also involve bak, bax and bcl-2, as shown with lovastatin in colon cancer cells (1), but other middle of G 1 and acts together with cyclin E to control progression though G 1 . With cyclin A cdk 2 may function in studies imply that caspase-7 may play a role in this process (49). It is possible that mevastatin may enhance the modulation controlling the start of DNA synthesis in the S phase (27, 31) . We could show that in Caco-2 cells mevastatin caused a of these apoptosis-related genes by butyrate to make cells become more susceptible to apoptosis. However, further studies significant down-regulation of cdk 4, cdk 6 and cyclin D1 protein with a concomitant up-regulation of the cell cycle are needed to assess the putative influence of mevastatin on apoptosis related genes in our cell line. inhibitors p21 and p27. This is in agreement with our data showing an arrest of cells in the G 1 phase after treatment with Mevalonate is a precursor for the synthesis of isoprenoids, which are required for post-transcriptional modification of mevastatin. It has been shown previously that butyrate inhibits cyclin D1 expression at the transcriptional level, an effect proteins like Ras (5,16). Our findings that addition of mevalonate, but not FPP or GGPP (two downstream intermediates of which probably could be enhanced by co-incubation with mevastatin (33) .
the mevalonate pathway), to the medium reversed the effects of mevastatin suggest that either Caco-2 cells are not The role of p21 and p27 in the regulation of cell proliferation, differentiation and apoptosis is still controversial (34). which both are unusual and only rarely require drug cessation (52-55). In in vivo experiments the dose of lovastatin used is has been shown that the increase of p21 and p27 was due to the inhibition of their ubiquitin-proteasome mediated proteo-~1.5-2.5 mg/kg weight per animal, which is only modestly Ͼ0.25-1.0 mg/kg weight used clinically in humans for lysis by the HRI lovastatin, resulting in an accumulation of p21 and p27 and a subsequent G 1 arrest (38,39). It is very lowering serum cholesterol (1) . In spite of the differences in pharmacokinetics between rats and humans, a reduction in likely that the same mechanism is responsible for the increase of the cdk inhibitors in our cell line Caco-2 by mevastatin, colon cancer incidence was noted with statins at doses used for coronary artery disease prophylaxis in clinical trials (10,11). although other pathways cannot be ruled out. However, our data suggest a role of p21 and p27 rather in apoptosis than in These observations suggest that lower doses than those used in the present study may be effective. In addition, the antidifferentiation, as the latter process is prevented by mevastatin in our cell line, as we have recently shown (40) .
tumour effect of statins may be of potential therapeutic interest in the light of the synergism between statins and other Cdk 2 protein expression decreased with butyrate treatment, which has been demonstrated earlier (27) , but was not chemopreventive agents, like butyrate, allowing lower effective doses of both agents. significantly altered by mevastatin. The same was true for cyclin E protein expression. This is in agreement with previous In summary, our data show that in the human adenocarcinoma cell line Caco-2 the HRI mevastatin synergistically data showing that in human prostate carcinoma cells lovastatin had no effect on cdk 2 and cyclin E protein expression (41) .
acts with butyrate to inhibit cell proliferation and to induce cell cycle arrest and apoptosis in this cell line. This seems to However, the butyrate-mediated down-regulation of cdk 2 and cyclin E, responsible for the progression of cells from G 1 to be associated with an early arrest of cells in G 0 /G 1 phase of the cell cycle and a late arrest in the G 2 /M phase, accompanied S phase of the cell cycle, could probably contribute to G 1 arrest. Taken together, analysis of cell cycle relevant proteins by a down-regulation of cdk 4, cdk 6 and cyclin D1 and an up-regulation of p21 and p27 protein expression. These results shows that mevastatin acts synergistically with butyrate to keep the cells in G 1 phase of the cell cycle by down-regulating suggest that induction of apoptosis together with the G 0 /G 1 and G 2 /M cell cycle arrest may be one of the mechanisms of the cell cycle promoting kinases cdk 4 and ckd 6 as well as their binding partner cyclin D1 and by increasing the cell the antiproliferative effect of mevastatin in colon cancer cells. As butyrate has a very short metabolic half-life of~6 min cycle inhibitors p21 and p27. However, it cannot be ruled out that other cell cycle related proteins, probably responsible for (56,57), the concomitant provision of HRI, like mevastatin, may serve to further enhance the butyrate effects. Thus, the 
